Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 249Rectal Neoplasms 154Pancreatic Neoplasms 125Stomach Neoplasms 105Colonic Neoplasms 104Esophageal Neoplasms 90Neoplasm Metastasis 69Breast Neoplasms 61Squamous Cell Carcinoma of Head and Neck 47Carcinoma, Hepatocellular 42Adenocarcinoma Of Esophagus 41Head and Neck Neoplasms 39Esophageal Squamous Cell Carcinoma 38Neoplasms 37Nasopharyngeal Carcinoma 30Adenocarcinoma 24Cholangiocarcinoma 20Keratosis, Actinic 17Carcinoma, Squamous Cell 16Biliary Tract Neoplasms 16Liver Neoplasms 15Gastrointestinal Neoplasms 15Anus Neoplasms 14Gallbladder Neoplasms 11Bile Duct Neoplasms 11Peritoneal Neoplasms 10Laryngeal Neoplasms 9Recurrence 8Nasopharyngeal Neoplasms 7Colorectal Cancer Metastatic 7

Interventions

irinotecan sucrosofate 1Oxaliplatin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Small Intestine Cancer × Fluorouracil × Clear all
NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

The Methodist Hospital Research Institute

Phase 1 Not yet recruiting
22 enrolled
Gastrointestinal

Advanced Small Intestine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡